Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age7-32
SponsorNationwide Children's Hospital

About this trial

Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment.

There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.

Eligibility criteria

Qualifiers

EPIs born between 22-weeks+0 days (220/7 wks) and 27-weeks+6 days (276/7 wks) gestation, inclusive

Admitted to a study NICU

Birth weight ≥700-grams

Mechanically ventilated at time of consent and randomization

Disqualifiers

Life-threatening congenital defects (including congenital heart disease such as aortic coarctation or pulmonary artery stenosis). PDA and small atrial/ventricular septal defects are permitted;

Congenital lung abnormalities, (e.g. restrictive lung disease);

Pharyngeal or airway anomalies (tracheal stenosis, choanal atresia);

Treatment for acute abdominal process (e.g., necrotizing enterocolitis);

Trial design

Treatments tested in this trial

  • Percutaneous Patent Ductus Arteriosus Closure (PPC)
  • Responsive Management Intervention
  • Echocardiogram, cardiac

Treatment groups

240 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Nationwide Children's Hospital

Lead sponsor

National Institutes of Health (NIH)

Collaborator

Abbott

Collaborator

University of Pittsburgh

Collaborator

University of Bristol

Collaborator

Dartmouth College

Collaborator

University of Iowa

Collaborator

Emory University

Collaborator

Cedars-Sinai Medical Center

Collaborator

Children's Hospital Los Angeles

Collaborator

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator